becaplermin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
platelet-derived growth factor	4925	165101-51-9

Description:

Molecule

Description

Synonyms:

becaplermin
rhPDGF-BB
RWJ-60235
RWJ 60235
regranex

A recombinant human platelet-derived growth factor B-chain dimer used to promote WOUND HEALING by stimulating PHYSIOLOGIC ANGIOGENESIS.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Dec. 16, 1997	FDA	OMJ PHARMACEUTICALS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Wound complication	196.70	79.97	31	324	3716	63484951
Toe amputation	108.26	79.97	17	338	1950	63486717
Osteomyelitis	89.24	79.97	22	333	25998	63462669

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Wound complication	256.20	57.37	42	495	2308	34954086
Osteomyelitis	159.96	57.37	39	498	16097	34940297
Toe amputation	105.33	57.37	20	517	2504	34953890
Cellulitis	91.00	57.37	33	504	52918	34903476
Application site infection	65.16	57.37	8	529	48	34956346

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Wound complication	294.18	49.28	50	794	4943	79738601
Osteomyelitis	195.22	49.28	49	795	32816	79710728
Toe amputation	174.79	49.28	31	813	3880	79739664
Cellulitis	114.77	49.28	43	801	109017	79634527
Application site infection	91.26	49.28	11	833	85	79743459
Wound infection staphylococcal	70.74	49.28	14	830	3130	79740414
Application site pain	70.67	49.28	15	829	4732	79738812
Gangrene	56.13	49.28	14	830	8950	79734594
Inappropriate schedule of product administration	54.44	49.28	27	817	133601	79609943

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A01AD08	ALIMENTARY TRACT AND METABOLISM STOMATOLOGICAL PREPARATIONS STOMATOLOGICAL PREPARATIONS Other agents for local oral treatment
ATC	D03AX06	DERMATOLOGICALS PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS CICATRIZANTS Other cicatrizants
FDA CS	M0017024	Platelet-Derived Growth Factor
MeSH PA	D043925	Angiogenesis Inducing Agents
MeSH PA	D000925	Anticoagulants
MeSH PA	D006133	Growth Substances
MeSH PA	D006401	Hematologic Agents
FDA EPC	N0000175885	Human Platelet-derived Growth Factor

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Neuropathic diabetic ulcer - foot	indication	201251005

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Platelet-derived growth factor receptor	Kinase	P09619 P16234	PGFRB_HUMAN PGFRA_HUMAN	AGONIST				DRUG LABEL	DRUG LABEL

External reference:

ID	Source
D03065	KEGG_DRUG
4021101	VUID
N0000148557	NUI
4021101	VANDF
CHEMBL1201556	ChEMBL_ID
DB00102	DRUGBANK_ID
115238	RXNORM
11521	MMSL
4248	MMSL
007329	NDDF
108936003	SNOMEDCT_US
386940001	SNOMEDCT_US
C0379135	UMLSCUI
D000077214	MESH_DESCRIPTOR_UI
7454	INN_ID
1B56C968OA	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
REGRANEX	HUMAN PRESCRIPTION DRUG LABEL	1	50484-810	GEL	100 ug	TOPICAL	BLA	28 sections